CSPIA
IMRX icon

Cary Street Partners Investment Advisory’s Immuneering IMRX Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-301
Closed -$3.05K – 1894
2023
Q2 		$3.05K Hold
301
– – ﹤0.01% 1520
2023
Q1 		$2.92K Buy
+301
New +$1.71K ﹤0.01% 1442

Other funds holding IMRX

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Cary Street Partners Investment Advisory's IMRX Position: Q3 2023 in Review

Cary Street Partners Investment Advisory sold out of Immuneering (IMRX) in Q3 2023, closing a stake of 301 shares — an estimated $3.05K sold.

Cary Street Partners Investment Advisory first reported a position in IMRX in Q1 2023 and held it in 2 quarters. The position peaked at $3.05K in Q2 2023. 52 funds tracked by Wall St. Rank hold IMRX as of Q3 2023.

  • Cary Street Partners Investment Advisory reported no remaining Immuneering position as of Q3 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 301 Immuneering shares in Q3 2023, an estimated $3.05K.
  • Cary Street Partners Investment Advisory first reported a position in Immuneering in Q1 2023 and held it in 2 quarters.
  • Cary Street Partners Investment Advisory's Immuneering position peaked at $3.05K in Q2 2023.
  • 52 funds tracked by Wall St. Rank held Immuneering as of Q3 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q3 2023, filed 13 Nov 2023.